Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape
Ecolab’s continued leadership position on renowned sustainability indices demonstrates the company’s record of advancing sustainable growth
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Innovent will supply sintilimab for the collaborated clinical trial
The product is expected to be launched in December 2023
AHHL is primarily engaged in nursing care, in home primary care, physiotherapy at home, sample collection, post-operative/post-surgical care
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
Furthering cell therapy ambition across oncology and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
